Fig. 1From: Optimal cumulative dose of cisplatin for concurrent chemoradiotherapy among patients with non-metastatic nasopharyngeal carcinoma: a multicenter analysis in ThailandPatient survival based on cumulative dose of cisplatin (mg/m2) during chemoradiotherapy. a Overall survival (OS), b Recurrence-free survival (RFS), c distant recurrence-free survival (DRFS), d Locoregional recurrence-free survival (LRFS)Back to article page